Dopamine receptor interacting proteins: Targeting neuronal calcium sensor-1/D2 dopamine receptor interaction for antipsychotic drug development

Current Drug Targets

Volumn 13, Issue 1, 2012, Pages 72-79

  Kabbani, Nadine ^a   Woll, Mathew P ^b   Nordman, Jacob C ^a   Levenson, Robert ^b  

^a GEORGE MASON UNIVERSITY   (United States)

^b PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

Calcium signaling; Drug design; Drug development; Schizophrenia; Therapeutics

Indexed keywords

CLOZAPINE; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR; HALOPERIDOL; NEUROLEPTIC AGENT; NEURONAL CALCIUM SENSOR; NEURONAL CALCIUM SENSOR 1; UNCLASSIFIED DRUG;

CALCIUM SIGNALING; DRUG DESIGN; DRUG TARGETING; FLUORESCENCE POLARIZATION IMMUNOASSAY; PROTEIN PHOSPHORYLATION; PROTEIN TRANSPORT; REVIEW; SCHIZOPHRENIA;

ANIMALS; ANTIPSYCHOTIC AGENTS; CALCIUM SIGNALING; DRUG DISCOVERY; GENE TARGETING; HUMANS; NEURONAL CALCIUM-SENSOR PROTEINS; NEUROPEPTIDES; PHOSPHORYLATION; PROTEIN TRANSPORT; RECEPTORS, DOPAMINE D2; SCHIZOPHRENIA; SIGNAL TRANSDUCTION;

EID: 84855858750     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/138945012798868515     Document Type: Review

References (59)

1. Bertorello AM, Hopfield JF, Aperia A, Greengard P. Inhibition by dopamine of (Na(+)K+) ATPase activity in neostriatal neurons through D1 and D2 dompamine receptor synergism. Nature 1990; 347: 386-88.
2. Goldman-Rakic PS. The cortical dopamine system: role in memory and cognition. Adv Pharmacol 1998; 42: 707-11.
3. Schultz W. Getting formal with dopamine and reward. Neuron 2002; 36: 241-63.
4. Albert PR, Neve KA, Bunzow JR, Civelli O. Coupling of a cloned rat dopamine D2 receptro to inhibition of adenylyl cyclase and prolactin secretion. J Biol Chem 1990; 265: 2098-104.
5. Missale C, Nash SR, Robinson SW, Jaber M, Caron MG. Dopamine receptors: from structure to function. Physiol Rev 1998; 78: 189-225.
6. Sidhu A, Niznik HB. Coupling of dopamine receptor subtypes to multiple and diverse G proteins. Int J Dev Neurosci 2000; 18: 669-77.
7. Obadian J, Avidor-Reiss T, Fishburn CS, et al. Adenylyl cyclase interaction with the D2 dopamine receptor family; differential coupling to Gi, Gz, and Gs. Cell Mol Neurobiol 1999; 19: 653-64.
8. Neve KA, Seamans JK, Trantham-Davidson H. Dopamine receptor signaling. J Recept Signal Transduct Res 2004; 24: 165-205.
9. Nicola SM, Surmeier J, Malenka RC. Dopaminergic modulation of neuronal excitability in the striatum and nucleus accumbens. Annu Rev Neurosci 2000; 23: 185-215.
10. Kabbani N, Hannan MA, Levenson R. Unraveling the Dopamine Receptor Signalplex by DRIPs and DRAPs. Curr Proteomics 2005; 2: 1-15.
11. Bockaert J, Roussignol G, Becamel C, et al. GPCR-interacting proteins (GIPs): nature and functions. Biochem Soc Trans 2004; 32: 851-5.
12. Millian G, White JH. Protein-protein interactions at G-proteincoupled receptors. Trends Pharmacol Sci 2001; 22: 513-8.
13. Girault JA, Greengard P. The neurobiology of dopamine signaling. Arch Neurol 2004; 61: 641-4.
14. Miyamoto S, Duncan GE, Marx CE, Lieberman JA. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry 2005; 10: 79-104.
15. Holden C. Deconstructing schizophrenia. Science 2003; 299: 333-5.
16. Frankle WG, Lerma J, Laruelle M. The synaptic hypothesis of schizophrenia. Neuron 2003; 39: 205-16.
17. Seeman P, Kapur S. Schizophrenia: More dopamine more D2 receptors. Proc Natl Acad Sci USA 2000; 97: 7673-5.
18. Glatt S, Faraone SV, Tsuang MT. Meta-analysis identifies an association between the dopamine D2 receptor gene and schizophrenia. Mol Psychiatry 2003; 8: 911-5.
19. Carlsson A. Antipsychotic drugs and catecholamine synapses. J Psychiatric Res 1974; 11: 57-64.
20. Kellendonk C, Simpson EH, Polan HJ, et al. Transient and selective overexpression of dopamine D2 receptors in the striatum causes persistent abnormalities in prefrontal cortex functioning. Neuron 2006; 49: 603-15.
21. Gao WJ, Goldman-Rakic PS. Selective modulation of excitatory and inhibitory microcircuits by dopamine. Proc Natl Acad Sci USA 2003; 100: 2836-41.
22. Bonci A, Hopf FW. The dopamine D2 receptor: New surprises from an old friend. Neuron 2005; 47: 335-8.
23. Pulver AE. Search for schizophrenia candidate genes. Biol Psychiatry 2000; 47: 221-30.
24. Owen MJ, Williams NM, O'Donovan MC. The molecular genetics of schizophrenia:new findings promise new insights. Mol Psychiatry 2004; 9: 14-27.
25. Kabbani N, Levenson R. A proteomic approach to receptor signaling: Molecular mechanisms and therapeutic implications derived from discovery of the dopamine D2 receptor signalplex. Eur J Pharm 2007; 572: 83-93.
26. Kabbani N, Negyessy L, Lin R, Goldman-Rakic P, Levenson R. Interaction with neuronal calcium sensor NCS-1 mediates desensitization of the D2 dopamine receptor. J Neurosci 2002; 22: 8476-86.
27. Koh PO, Undie AS, Kabbani N, Goldman-Rakic PS, Levenson R, Lidow MS. Upregulation of neuronal calcium sensor-1 (NCS-1) in the prefrontal cortex of schizophrenic and bipolar patients. Proc Natl Acad Sci USA 2003; 100: 313-7.
28. Bai J, He F, Novikova SI, et al. Abnormalities in the dopamine system in schizophrenia may lie in altered levels of dopamine receptor-interacting proteins. Biol Psychiatry 2004; 56: 427-40.
29. Bergson C, Levenson R, Goldman-Rakic PS, Lidow MS. Dopamine receptor interacting proteins: The calcium connection in dopamine signaling. Trends Pharmacol Sci 2003; 24: 486-92.
30. Dedier S, Reinelt S, Rion S, Folkers G, Rognan D. Use of fluorescence polarization to monitor MHC-peptide interactions in solution. J Immunol Methods 2001; 255: 57-66.
31. Jameson DM, Seifried SE. Quantification of protein-protein interactions using fluorescence polarization. Methods 1999; 19: 222-33.
32. Harvey SC, Cheung HC. Computer simulation of fluorescence depolarization due to brownian motion. Proc Natl Acad Sci USA 1972; 69: 3670-2.
33. Weber G. Polarization of the fluorescence of macromolecules. I. Theory and experimental method. Biochem J 1952; 51: 145-55.
34. Roehrl MH, Wang JY, Wagner G. A general framework for development and data analysis of competitive high-throughput screens for small-molecule inhibitors of proteinprotein interactions by fluorescence polarization. Biochemistry 2004; 43: 16056-66.
35. Owicki JC. Fluorescence polarization and anisotropy in high throughput screening: perspectives and primer. J Biomol Screen 2000; 5: 297-306.
36. Zhang JH, Chung TD, Oldenburg KR. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 1999; 4: 67-73.
37. Roberts E, Wendel J. Dynamic modelling of the binding of substances to the conserved membrane-adjacent heptapeptide of the 15-residue C-terminal cytoplasmic fragment of mammalian dopamine D2 receptors. Neurochem Res 1996; 21(2): 177-200.
38. Skaper SD, Walsh FS. Neurotrophic molecules: strategies for designing effective therapeutic molecules in neurodegeneration. Mol Cell Neurosci 1998; 12: 179-93.
39. Scarselli M, Novi F, Schallmach E, et al. D2/D3 dopamine receptor heterodimers exhibit unique functional properties. J Biol Chem 2001; 276: 30308-14.
40. Zou S, Li L, Pei L, et al. Protein-protein coupling/uncoupling enables dopamine D2 receptor regulation of AMPA receptormediated excitotoxicity. J Neurosci 2005; 25: 4385-95.
41. Kearn CS, Blake-Palmer K, Daniel E, Mackie K, Glass M. Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors enhances heterodimer formation: a mechanism for receptor cross-talk? Mol Pharmacol 2005; 67: 1697-704.
42. Ferre S, Ciruela F, Canals M, et al. Adenosine A2A-dopamine D2 receptor-receptor heteromers. Targets for neuro-psychiatric disorders. Parkinsonism Relat Disord 2004; 10: 265-71.
43. Rocheville M, Lange DC, Kumar U, Patel SC, Patel RC, Patel YC. Receptors for dopamine and somatostatin: formation of heterooligomers with enhanced functional activity. Science 2000; 288: 154-7.
44. Liu XY, Chu XP, Mao LM, et al. Modulation of D2 receptor-NR2B interactions in response to cocaine. Neuron 2006; 52: 897-909.
45. Lavine N, Ethier N, Oak JN, et al. G protein-coupled receptors form stable complexes with inwardly rectifying potassium channels and adenylyl cyclase. J Biol Chem 2002; 277: 46010-9.
46. Binda AV, Kabbani N, Lin R, Levenson R. D2 and D3 Dopamine Receptor Cell Surface Localization Mediated by Interaction with Protein 4.1N. Mol Pharmacol 2002; 62: 507-13.
47. Macey TA, Gurevich VV, Neve KA. Preferential Interaction between the dopamine D2 receptor and Arrestin2 in neostriatal neurons. Mol Pharmacol 2004; 66: 1635-42.
48. Kabbani N, Jeromin A, Levenson R. Dynamin-2 associates with the dopamine receptor signalplex and regulates internalization of activated D2 receptors. Cell Signal 2004; 16: 497-503.
49. Lin R, Karpa KD, Kabbani N, Goldman-Rakic P, Levenson R. Dopamine D2 and D3 receptors are linked to the actin cytoskeleton via interaction with Filamin A. Proc Natl Acad Sci USA 2001; 98: 5258-63.
50. Bartlett SE, Enquist J, Hopf FW, et al. Dopamine responsiveness is regulated by targeted sorting of D2 receptors. Proc Natl Acad Sci USA 2005; 102: 11521-6.
51. Jeanneteau F, Diaz J, Sokoloff P, Griffon N. Interactions of GIPC with dopamine D2, D3 but not D4 receptors define a novel mode of regulation of G protein-coupled receptors. Mol Biol Cell 2004; 15: 696-705.
52. Takeuchi Y, Fukunaga K. Differential subcellular localization of two dopamine D2 receptor isoforms in transfected NG108-15 cells. J Neurochem 2003; 85: 1064-74.
53. Free RB, Hazelwood LA, Cabrera DM, et al. D1 and D2 dopamine receptor expression is regulated by direct interaction with the chaperone protein calnexin. J Biol Chem 2007; 282(29): 21285-300.
54. Bofill-Cardona E, Kudlacek O, Yang Q, Ahorn H, Freissmuth M, Nanoff C. Binding of calmodulin to the D2-dopamine receptor reduces receptor signaling by arresting the G protein activation switch. J Biol Chem 2000; 275: 32672-80.
55. Park SK, Nguyen MD, Fischer A, et al. Par-4 links dopamine signaling and depression. Cell 2005; 122: 275-87.
56. Ghavami A, Hunt RA, Olsen MA, et al. Differential effects of regulator of G protein signaling (RGS) proteins on serotonin 5-HT1A, 5-HT2A, and dopamine D2 receptor-mediated signaling and adenylyl cyclase activity. Cell Signal 2004; 16: 711-21.
57. Li M, Bermak JC, Wang ZW, Zhou QY. Modulation of dopamine D(2) receptor signaling by actin-binding protein (ABP-280). Mol Pharmacol 2000; 57: 446-52.
58. Lee FJ, Xue S, Pei L, et al. Dual regulation of NMDA receptor functions by direct protein-protein interactions with the dopamine D1 receptor. Cell 2002; 111: 219-30.
59. De Cotiis DA, Woll MP, Levenson R, Flanagan JM. Optimized Expression and Purification of Myristoylated NCS-1 in E. coli. Protein Expr Purif 2008; 61:103-12.